Have you looked at the pps lately? It is down about 40% from ASCO. If the data you expect is so good, why has the share price been cut almost in half? It makes no sense unless the data is questionable and ambiguous.
The market players almost assuredly know what is going on. It is almost a certain bet that the primary and secondary endpoints have been missed. The mOS of 23.1 months just does not yield enough of a cushion and that is measured from surgery! Avoiding talking about PFS most probably means that that endpoint was missed and that they are trying to save it with adjudication. If even with adjudication the PFS endpoint is not met, look out below!
No wonder they went with an amended SAP the size of a telephone book as DI told some MB members. Top line is going to be confusing and create more questions than answers. I get the frightening feeling that the top line data will not be clearly undeniable. It won't speak for itself. There will be endless, complex, confusing and questionable analysis trying to spin the data in a positive light long after top line announcement.
I think announcement of top line will be extremely disappointing and with NWBO management's penchant for lack of transparency for fear of upsetting the RAs, revelation of top line will be a nebulous event. Instead of the pps going up, they will hit single digits. RA approvals will be at least a year away, assuming they issue, and the uncertainty of approval plus extremely toxic financing will drive the pps to new lows even after an almost certain disastrous R/S.
NWBO's excessive and unfounded fear of the FDA has impelled management to follow a disastrous strategy of silence and parsimonious revelation when they do say something that engenders obfuscation and encourages a complete lack of credibility.
I am afraid that top line revelation won't happen this year. Maybe that's a good thing. Next stop, mid-teens just as I predicted many months ago. You can thank NWBO management. Disgusting. JMHO
